<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658654</url>
  </required_header>
  <id_info>
    <org_study_id>72476</org_study_id>
    <nct_id>NCT04658654</nct_id>
  </id_info>
  <brief_title>Cognitive Effects of Roflumilast in MCI Patients</brief_title>
  <acronym>ROMEMA</acronym>
  <official_title>A Proof of Concept Phase II Study With the PDE-4 Inhibitor Roflumilast in Patients With Mild Cognitive Impairment (MCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current project is to validate whether chronic intake (24 weeks) roflumilast&#xD;
      (PDE4 inhibitor) can improve cognition in clinical patients with mild cognitive impairment&#xD;
      (MCI). The project will demonstrate whether episodic memory, but also attention, information&#xD;
      processing or executive function improves with chronic administration of roflumilast in MCI&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Verbal Learning Test (VLT) (15 words)</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's disease Assessment Scale- Cognitive Sub-scale (ADAS-Cog scale)</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini Mental State Examination (MMSE)</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern Separation Task</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail-Making Test (TMT)</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Letter Digit Substitution Test (LDST)</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's disease co-operative study activities of daily living (ADCS-ADL) scale</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL-AD</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Conversion to Alzheimer's disease (AD)</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic validation of roflumilast and its active metabolite roflumilast N-Oxide in plasma</measure>
    <time_frame>Acute, 12 weeks chronic intake and 24 weeks chronic intake</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Tau in tears</measure>
    <time_frame>Change from baseline to 24 weeks of chronic intake</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral capsule, once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roflumilast 50ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roflumilast (50 microgram) oral capsule, once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roflumilast 100ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roflumilast (100 microgram) oral capsule, once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>chronic intervention (24 weeks): roflumilast capsule</description>
    <arm_group_label>Roflumilast 100ug</arm_group_label>
    <arm_group_label>Roflumilast 50ug</arm_group_label>
    <other_name>EU: Daxas</other_name>
    <other_name>US: Daliresp</other_name>
    <other_name>PDE4 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Pill with inactive ingredients to mimic same appearance of roflumilast capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  50 to 90 years of age&#xD;
&#xD;
          -  Willingness (including the informal caregiver) to sign an informed consent&#xD;
&#xD;
          -  Body mass index (BMI) between 18.5 and 30&#xD;
&#xD;
          -  MMSE of 20 or higher&#xD;
&#xD;
          -  MCI due to AD diagnosis&#xD;
&#xD;
          -  Memory performance on the delayed recall in the clinically relevant 15 words VLT has&#xD;
             to be 1-2 SD below the average, as well as increased cerebrospinal fluid (CSF) Ab&#xD;
             marker and/or a positive biomarker of neuronal injury (MRI scan including measurements&#xD;
             of decreased hippocampal volume or medial temporal atrophy by volumetric measures or&#xD;
             visual rating)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Normal Pressure Hydrocephalus (NPH)&#xD;
&#xD;
          -  Morbus Huntington&#xD;
&#xD;
          -  Parkinson's disease&#xD;
&#xD;
          -  HIV/AIDS&#xD;
&#xD;
          -  Hepatitis C &amp; B&#xD;
&#xD;
          -  Recent Transient Ischemic Attack (TIA) (&lt; 2 years)&#xD;
&#xD;
          -  Cerebrovascular Accident (CVA) (&lt; 2 years)&#xD;
&#xD;
          -  TIA/CVA followed by cognitive decline (within 3 months)&#xD;
&#xD;
          -  Chronic Obstructive Pulmonary Disease (COPD) and asthma&#xD;
&#xD;
          -  History of schizophrenia, bipolar disorder or psychotic symptoms not otherwise&#xD;
             specified or previous treatment for these diseases (lifetime)&#xD;
&#xD;
          -  Current affective disorder (i.e. anxiety or major depression)&#xD;
&#xD;
          -  Cognitive problems due to alcohol abuse, brain tumor, epilepsy, encephalitis or lack&#xD;
             of capacity to consent to participation.&#xD;
&#xD;
          -  Current treatment with (or illicit use of) centrally acting beta-blockers, cannabis,&#xD;
             opiates, benzodiazepines, MDMA and cocaine&#xD;
&#xD;
          -  Patients with moderate or major liver impairments will be excluded (e.g. Child-Pugh B&#xD;
             and C).&#xD;
&#xD;
          -  Use of medication showing strong inhibition of either CYP3A4 or CYP1A2&#xD;
&#xD;
          -  Patients with rare hereditary problems of galactose intolerance, Lapp lactase&#xD;
             deficiency or glucose-galactose malabsorption&#xD;
&#xD;
          -  Patients participating in other drug studies&#xD;
&#xD;
          -  If patient does not have the possibility to be accompanied by the same informal&#xD;
             caregiver during all test days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inez Ramakers, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatry and Neuropsychology, FHML, Maastricht University, the Netherlands.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frans Verhey, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Psychiatry and Neuropsychology, FHML, Maastricht University, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arjan Blokland, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neuropsychology &amp; Psychopharmacology, FPN, Maastricht University, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jos Prickaerts, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatry and Neuropsychology, FHML, Maastricht University, the Netherlands.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina Possemis, MSc.</last_name>
    <phone>+31 (0)43 388 1022</phone>
    <email>n.possemis@maastrichtuniversity.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inez Ramakers, Dr.</last_name>
    <email>i.ramakers@maastrichtuniversity.nl</email>
  </overall_contact_backup>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phosphodiesterase 4 Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

